Healthcare & Life Sciences
FDA, TGA and EMA enforcement exposure has made regulatory reflex a non-negotiable successor attribute. We deliver leadership that survives a Complete Response Letter, a 483 and a TGA recall in the same quarter.
Healthcare boards face simultaneous pressure from regulatory enforcement, payor consolidation, AI-enabled diagnostics review, and pipeline-attrition risk. We have placed CEO, Chief Medical Officer, Chief Scientific Officer, General Counsel and Audit Committee Chair benches across pharma, medtech, listed health systems and digital-health platforms.
Pharma, medtech, listed health systems, payors, and digital-health platforms.
Including 5 of the top-10 by global prescription revenue.
Calibrated for FDA, TGA and EMA enforcement reflex and AI-diagnostics regulatory readiness.
Successor inventories deployed during active FDA consent-decree or warning-letter regimes.
478 mandates across four regions.
We deliver this sector out of five global hubs — Sydney (HQ), Singapore, London, New York and Dubai — anchored to discrete supervisory regimes. Regional Managing Partners hold the primary client relationship; the global sector lead governs methodology, calibration and quality.
Sydney · Singapore · Tokyo · Seoul
TGA-regulated listed pharma, PMDA-supervised majors, MOFCOM-reviewed cross-border.
London · Basel · Frankfurt · Copenhagen
EMA-supervised Big Pharma, FTSE 100 medtech, Nordic biotech.
New York · Boston · Toronto
FDA-regulated listed pharma, NIH-grant biotech, Health Canada-supervised payors.
Dubai · Riyadh
Sovereign biotech programmes, GCC health systems, sovereign-fund pharma holdings.
What we are calibrated to deliver.
CMO scoring against FDA 483 response history, EMA referral experience and TGA recall management.
Slates calibrated for FDA AI/ML SaMD Action Plan and EU AI Act high-risk medical-device obligations.
Successor scoring tuned to Phase II/III pivot, commercial-launch and patent-cliff phase requirements.
MOFCOM, CMA, FTC and EC merger-review readiness embedded into chair and General Counsel benches.
The exposure pattern we price into every slate.
Successor CEOs must demonstrate 483 and Complete Response Letter response history at scale.
FDA AI/ML SaMD framework now imposes board-level oversight obligations on diagnostic-AI deployment.
Sustained Phase III failure rate above sector mean is a leading indicator of CEO removal within 18 months.
Single-payor revenue concentration above 25% materially elevates CEO derailment under reimbursement re-pricing.
Anonymised by code; defensible by record.
Every engagement opens under NDA-by-default discretion. The mandates below are surfaced with code, region, remit and outcome — the underlying entity, candidate and counterparty detail remains under confidentiality envelope and is only disclosable on engagement under reciprocal NDA.
Successor pair installed within 8 weeks; closed consent decree 9 months ahead of schedule and recovered $4.1bn in market cap.
Replaced CMO ahead of EMA referral; preserved licence-to-operate across 23 EU markets and 4 UK product lines.
Dual succession executed under TGA review; first medtech CEO in region with combined FDA + TGA + PMDA reporting reflex.
Inaugural CAIO/CMO joint role under FDA SaMD framework; appointee chaired AI-governance committee for downstream clinical-trial pipeline.
The regulatory regimes encoded into every successor score.
Each successor in this sector is scored against the regimes below. The skills-matrix is refreshed continuously by the firm's Regulatory Architect team as supervisory expectations migrate — the most recent calibration was applied to every live slate in the current quarter.
Encoded into chair and CMO bench requirements as enforcement-reflex evidence.
AI-diagnostics governance encoded into board-level skills matrix.
Post-Brexit UK pharmacovigilance reflex scored separately from EMA.
Pivot-stage CMO scoring against trial-conduct integrity standards.
Brief the Healthcare & Life Sciences practice lead.
Every sector engagement opens under NDA-by-default discretion and is governed by the regional Managing Partner. Initial briefings are conducted in person or under secure-channel video — never over open email.